14838
Progression in the field has taken a recent step forward with the approval of ruxolitinib ( Jakafi ) , a selective inhibitor of JAK1 / 2 and very recently tofacitinib ( Xeljanz ) , a pan - JAK inhibitor .
 Chemical: ruxolitinib; Chemical: Jakafi; Chemical: tofacitinib; Chemical: Xeljanz
Please list all entity words in the text that fit the category.Output format is "type1: word1; type2: word2". 
Option: Chemical 
Text: {0} 
Answer:
 Chemical: ruxolitinib; Chemical: Jakafi; Chemical: tofacitinib; Chemical: Xeljanz